CN112384625A - 重组aav载体及其使用方法 - Google Patents

重组aav载体及其使用方法 Download PDF

Info

Publication number
CN112384625A
CN112384625A CN201980039197.0A CN201980039197A CN112384625A CN 112384625 A CN112384625 A CN 112384625A CN 201980039197 A CN201980039197 A CN 201980039197A CN 112384625 A CN112384625 A CN 112384625A
Authority
CN
China
Prior art keywords
seq
sequence
recombinant
cox10
recombinant aav2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980039197.0A
Other languages
English (en)
Chinese (zh)
Inventor
赛日·费杜斯
巴雷特·卡茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cherish Biological Co ltd
Original Assignee
Cherish Biological Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cherish Biological Co ltd filed Critical Cherish Biological Co ltd
Publication of CN112384625A publication Critical patent/CN112384625A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0026—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5)
    • C12N9/0028—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5) with NAD or NADP as acceptor (1.5.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0053—Oxidoreductases (1.) acting on a heme group of donors (1.9)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y106/00—Oxidoreductases acting on NADH or NADPH (1.6)
    • C12Y106/05—Oxidoreductases acting on NADH or NADPH (1.6) with a quinone or similar compound as acceptor (1.6.5)
    • C12Y106/05003—NADH dehydrogenase (ubiquinone) (1.6.5.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y109/00—Oxidoreductases acting on a heme group of donors (1.9)
    • C12Y109/03—Oxidoreductases acting on a heme group of donors (1.9) with oxygen as acceptor (1.9.3)
    • C12Y109/03001—Cytochrome-c oxidase (1.9.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201980039197.0A 2018-06-11 2019-06-11 重组aav载体及其使用方法 Pending CN112384625A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862683501P 2018-06-11 2018-06-11
US62/683,501 2018-06-11
PCT/US2019/036487 WO2019241206A1 (en) 2018-06-11 2019-06-11 Recombinant aav vectors and methods of using the same

Publications (1)

Publication Number Publication Date
CN112384625A true CN112384625A (zh) 2021-02-19

Family

ID=67138055

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980039197.0A Pending CN112384625A (zh) 2018-06-11 2019-06-11 重组aav载体及其使用方法

Country Status (8)

Country Link
US (1) US20210189424A1 (https=)
EP (1) EP3802840A1 (https=)
JP (1) JP7470057B2 (https=)
KR (1) KR102946006B1 (https=)
CN (1) CN112384625A (https=)
AU (1) AU2019286386B2 (https=)
CA (1) CA3103231A1 (https=)
WO (1) WO2019241206A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240014102A (ko) 2018-06-29 2024-01-31 우한 뉴로프스 바이오테크놀로지 리미티드 컴퍼니 레버 유전성 시신경병증의 치료를 위한 조성물 및 방법
CA3109432A1 (en) * 2018-08-20 2020-02-27 Wuhan Neurophth Biotechnology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
CN113025633B (zh) 2019-12-09 2024-08-27 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
CN115710585B (zh) * 2021-08-23 2025-03-28 纽福斯(苏州)生物科技有限公司 编码nd4的核酸及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008101233A2 (en) * 2007-02-16 2008-08-21 University Of Florida Research Foundation Inc. Mitochondrial nucleic acid delivery systems
US20090306188A1 (en) * 2005-05-03 2009-12-10 Inserm (Institut National De Al Sante Et De Al Rec Importation of mitochondrial protein by an enhanced allotopic approach
CN102634527A (zh) * 2012-04-11 2012-08-15 华中科技大学同济医学院附属同济医院 重组人nadh脱氢酶亚单位4基因及其表达载体构建方法
CN104450747A (zh) * 2014-09-23 2015-03-25 李斌 用于治疗Leber遗传性视神经病变的重组腺相关病毒-NADH脱氢酶亚单位4基因全长以及药剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218117B1 (en) * 1998-06-15 2001-04-17 Mitokor Compositions and methods for identifying agents that quantitatively alter detectable extramitochondrial DNA:mitochondrial DNA ratios
DE102010013829A1 (de) * 2010-03-26 2011-09-29 Carl Zeiss Microlmaging Gmbh Mikroskop und Verfahren zur Erfassung von Probenlicht
TWI775096B (zh) * 2012-05-15 2022-08-21 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
KR102244434B1 (ko) * 2014-08-11 2021-04-23 삼성전자주식회사 재조합 벡터 및 이를 이용한 목적 폴리펩타이드의 생산 방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090306188A1 (en) * 2005-05-03 2009-12-10 Inserm (Institut National De Al Sante Et De Al Rec Importation of mitochondrial protein by an enhanced allotopic approach
WO2008101233A2 (en) * 2007-02-16 2008-08-21 University Of Florida Research Foundation Inc. Mitochondrial nucleic acid delivery systems
CN102634527A (zh) * 2012-04-11 2012-08-15 华中科技大学同济医学院附属同济医院 重组人nadh脱氢酶亚单位4基因及其表达载体构建方法
CN104450747A (zh) * 2014-09-23 2015-03-25 李斌 用于治疗Leber遗传性视神经病变的重组腺相关病毒-NADH脱氢酶亚单位4基因全长以及药剂

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MACAULAY.V ET AL.: "Homo sapiens isolate 2_D4b2b(Tor50) mitochondrion, complete genome, ACCESSION:AY963573 REGION:10759-12136", GENBANK, vol. 1, pages 129 - 2 *
刘恩岐等: "真核细胞基因表达系统", 人类疾病动物模型, pages 6 *
贾战生: "肝病细胞治疗：基础与临床", vol. 1, 30 April 2005, 人民卫生出版社, pages: 409 *

Also Published As

Publication number Publication date
JP2021526834A (ja) 2021-10-11
KR102946006B1 (ko) 2026-03-30
AU2019286386B2 (en) 2025-05-29
US20210189424A1 (en) 2021-06-24
CA3103231A1 (en) 2019-12-19
AU2019286386A1 (en) 2021-01-28
WO2019241206A1 (en) 2019-12-19
AU2019286386A8 (en) 2021-02-11
EP3802840A1 (en) 2021-04-14
JP7470057B2 (ja) 2024-04-17
KR20210123285A (ko) 2021-10-13

Similar Documents

Publication Publication Date Title
KR102946006B1 (ko) 재조합 aav 벡터 및 그 이용 방법
KR20220022107A (ko) 유전자 전달을 위한 재조합 아데노-연관 바이러스 벡터
CN108753824B (zh) 用于治疗视网膜营养不良的病毒载体
KR102450833B1 (ko) 혈우병 a 치료용 유전자 요법
KR102691097B1 (ko) 표적 특이적 crispr 변이체
KR101471445B1 (ko) 조류에서 이식유전자 발현
KR20210151916A (ko) 뒤시엔느 근육 이영양증의 치료를 위한 aav 벡터-매개된 큰 돌연변이 핫스팟의 결실
CN110467679B (zh) 一种融合蛋白、碱基编辑工具和方法及其应用
CN109069668B (zh) 用于眼病的基因疗法
KR20230091894A (ko) 부위 특이적 표적화 요소를 통한 프로그램 가능한 첨가(paste)를 사용하는 부위 특이적 유전 공학을 위한 시스템, 방법, 및 조성물
KR20220161297A (ko) 신규 세포주
KR101449587B1 (ko) 장기 지속형 약물 제형
CN111733174B (zh) 一种分离的核酸分子及其用途
CN113106124B (zh) 表达cyp4v2的aav载体及其用途
KR20220030205A (ko) 면역 세포의 트랜스포존 기반 변형
KR20220163950A (ko) Aav 생산을 위한 이중 이기능성 벡터
KR20210151785A (ko) 비바이러스성 dna 벡터 및 fviii 치료제 발현을 위한 이의 용도
KR101591887B1 (ko) 장기 지속형 약물 제형
AU2018254529B2 (en) Therapeutic genome editing in Wiskott-Aldrich syndrome and X-linked thrombocytopenia
CN114350710A (zh) 编码vegf拮抗剂的多核苷酸表达盒、重组病毒及相关应用
CN111500635B (zh) 一种包含携带核酸分子的载体的试剂盒
CN112203697A (zh) 编码氨基己糖苷酶alpha和beta亚基的双顺反子AAV载体及其用途
US5955368A (en) Expression system for clostridium species
AU780854B2 (en) Hormone-hormone receptor complexes and nucleic acid constructs and their use in gene therapy
CN101652475A (zh) 在禽类中进行转基因表达

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination